Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Stage IV Pancreatic Cancer
NCT00003531Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Apr 1996
- Primary completion
- Jul 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of antineoplaston A10, antineoplaston AS2-1 in pancreatic adenocarcinoma (PDAC), sponsored by Burzynski Research Institute. Started Apr 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00003531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003531.